Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is a biotech company that is primarily focused on the development of Ampligen, a dsRNA molecule, for the treatment of various types of cancer, including late-stage pancreatic cancer. The company has a positive outlook, with upcoming catalysts expected from clinical data and a focus on a high-reward market. Additionally, the company has a strong balance sheet with enough cash into late-2026 and a current valuation that reflects its potential for high growth and upside opportunities. While there are risks associated with the long development road of its oncology drugs, the potential billion-dollar market presents a high reward for investors.

Bears say

AIM ImmunoTech is currently facing financial challenges as reflected by its weak balance sheet and repeated fundraising activities. Moreover, its recent Q4 results showed a higher-than-expected net loss, which could impact investor confidence. However, with a promising pipeline focused on important areas of unmet medical needs and a current attractive valuation, the company may still have potential for growth in the long term.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.